Drug Trial Radar · NCT05735184
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Last checked: Nov 21, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jul 18, 2023
Primary completion
Apr 2030
Study completion Apr 2030
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.
Conditions
- Acute Myeloid Leukemia
- Mixed Lineage Leukemia Gene Mutation
- Refractory AML
- AML With Mutated NPM1
- Acute Myeloid Leukemia Recurrent
- Acute Myeloid Leukemia, in Relapse
- NPM1 Mutation
- KMT2Ar
- Myeloid Sarcoma
- Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
ZiftomenibDrug
Oral Administration
VenetoclaxDrug
Oral Administration
AzacitidineDrug
Subcutaneous or Intravenous Administration
DaunorubicinDrug
Intravenous Administration
CytarabineDrug
Intravenous Administration
QuizartinibDrug
Oral Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only)Time frame: During the first 28 days of ziftomenib in combination with SOC backbone treatment (1 cycle)
- Descriptive statistics of adverse eventsTime frame: From Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment
- Complete remission (CR) rateTime frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic - Phoenix
Phoenix, Arizona · Recruiting
Moores UC San Diego Cancer Center
La Jolla, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA - Bowyer Oncology Center
Los Angeles, California · Recruiting
UC Irvine Health Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Yale Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Emory Healthcare - The Emory Clinic
Atlanta, Georgia · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Recruiting
University of Iowa Hospitals & Clinics
Iowa City, Iowa · Recruiting
The University of Kansas Medical Center Research Institute
Fairway, Kansas · Recruiting
University of Kentucky Markey Cancer Center
Louisville, Kentucky · Recruiting
Norton Cancer Institute - St. Matthews
Louisville, Kentucky · Recruiting
Ochsner MD Anderson Cancer Center
Jefferson, Louisiana · Recruiting
Johns Hopkins School of Medicine
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
UMass Chan Medical School
Worcester, Massachusetts · Recruiting
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
New York - Presbyterian / Weill Cornell Medicine
New York, New York · Recruiting
Mount Sinai - Ruttenberg Treatment Center
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
Duke Blood Cancer Center
Durham, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio · Recruiting
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
TriStar Bone Marrow Transplant
Nashville, Tennessee · Recruiting
Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin
Austin, Texas · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.